Gefitinib, a first generation EGFR-TKI for treating NSCLC, has low cerebrospinal fluid-to-plasma ratio of about 0.3%–1.3% in patients with BM [3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.